• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

S100A6、钙网蛋白和细胞鸟苷酸交换因子2作为系统性硬化症患者皮肤受累的生物标志物：一项病例对照研究

S100A6, Calumenin and Cytohesin 2 as Biomarkers for Cutaneous Involvement in Systemic Sclerosis Patients: A Case Control Study.

作者信息

Balanescu Paul, Balanescu Eugenia, Baicus Cristian, Balanescu Anca

机构信息

Internal Medicine Chair, University of Medicine and Pharmacy Carol Davila, 020021 Bucharest, Romania.

Clinical Immunology Laboratory CDPC, Colentina Clinical Hospital, 020125 Bucharest, Romania.

出版信息

J Pers Med. 2021 May 2;11(5):368. doi: 10.3390/jpm11050368.

DOI:10.3390/jpm11050368
PMID:34063287
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8147492/
Abstract

BACKGROUND

Systemic sclerosis (Ssc) is an autoimmune disease with incomplete known physiopathology. There is a high number of candidate proteomic biomarkers for Ssc that have not yet been confirmed on independent Ssc cohorts. The aim of the study was to confirm circulating S100A6, calumenin, and cytohesin 2 as biomarkers for Ssc.

METHODS

53 Ssc patients and 26 age- and gender-matched controls were included. Serum S100A6, calumenin, and cytohesin 2 were evaluated with commercial ELISA kits. Associations between serum expression and clinical Ssc characteristics were evaluated.

RESULTS

Serum calumenin, S100A6, and cytohesin 2 were higher in Ssc patients compared to controls. Calumenin associated with extensive cutaneous fibrosis, frequency of Raynaud phenomenon, and low complement level, and had a tendency to be higher in Ssc patients with pulmonary fibrosis. S100A6 correlated with the number of active digital ulcers. Serum cytohesin 2 levels were higher in patients with teleangiectasia and associated with pulmonary artery pressure.

CONCLUSIONS

Serum calumenin, S100A6, and cytohesin 2 were confirmed as biomarkers on an independent group of Ssc patients. Calumenin had the best predictive capacity for cutaneous Ssc manifestations. Future studies are needed to evaluate the prognostic value of these biomarkers and evaluate them as possible therapeutic targets.

摘要

背景

系统性硬化症（Ssc）是一种自身免疫性疾病，其生理病理学尚不完全清楚。有大量系统性硬化症的候选蛋白质组学生物标志物，但尚未在独立的系统性硬化症队列中得到证实。本研究的目的是确认循环中的S100A6、钙网蛋白和细胞鸟苷酸交换因子2（cytohesin 2）作为系统性硬化症的生物标志物。

方法

纳入53例系统性硬化症患者和26例年龄及性别匹配的对照。使用商用酶联免疫吸附测定（ELISA）试剂盒评估血清中的S100A6、钙网蛋白和细胞鸟苷酸交换因子2。评估血清表达与系统性硬化症临床特征之间的关联。

结果

与对照组相比，系统性硬化症患者血清中的钙网蛋白、S100A6和细胞鸟苷酸交换因子2水平更高。钙网蛋白与广泛的皮肤纤维化、雷诺现象的发生率和低补体水平相关，并且在患有肺纤维化的系统性硬化症患者中往往更高。S100A6与活动性指端溃疡的数量相关。患有毛细血管扩张的患者血清细胞鸟苷酸交换因子2水平更高，且与肺动脉压相关。

结论

血清钙网蛋白、S100A6和细胞鸟苷酸交换因子2在一组独立的系统性硬化症患者中被确认为生物标志物。钙网蛋白对皮肤系统性硬化症表现具有最佳预测能力。未来需要进行研究以评估这些生物标志物的预后价值，并将它们作为可能的治疗靶点进行评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c466/8147492/7026325ebc94/jpm-11-00368-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c466/8147492/006247c6432f/jpm-11-00368-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c466/8147492/c1c7e35492af/jpm-11-00368-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c466/8147492/ec7fb7a8627d/jpm-11-00368-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c466/8147492/7026325ebc94/jpm-11-00368-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c466/8147492/006247c6432f/jpm-11-00368-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c466/8147492/c1c7e35492af/jpm-11-00368-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c466/8147492/ec7fb7a8627d/jpm-11-00368-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c466/8147492/7026325ebc94/jpm-11-00368-g004.jpg

相似文献

1
S100A6, Calumenin and Cytohesin 2 as Biomarkers for Cutaneous Involvement in Systemic Sclerosis Patients: A Case Control Study.S100A6、钙网蛋白和细胞鸟苷酸交换因子2作为系统性硬化症患者皮肤受累的生物标志物：一项病例对照研究
J Pers Med. 2021 May 2;11(5):368. doi: 10.3390/jpm11050368.
2
Circulating Reticulocalbin 1 and Reticulocalbin 3 in Systemic Sclerosis Patients: Results of a Case Control Study.系统性硬化症患者循环中的网织钙结合蛋白1和网织钙结合蛋白3：一项病例对照研究的结果
Clin Lab. 2016;62(6):1109-16.
3
Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers.肺纤维化合并系统性硬化症的支气管肺泡灌洗液蛋白质组学分析：S100A6 和 14-3-3ε 作为潜在的生物标志物。
Rheumatology (Oxford). 2019 Jan 1;58(1):165-178. doi: 10.1093/rheumatology/key223.
4
Analysis of bronchoalveolar lavage fluid proteome from systemic sclerosis patients with or without functional, clinical and radiological signs of lung fibrosis.对伴有或不伴有肺纤维化功能、临床及放射学征象的系统性硬化症患者支气管肺泡灌洗液体蛋白质组的分析。
Arthritis Res Ther. 2006;8(6):R160. doi: 10.1186/ar2067.
5
Circulatory cytokeratin 17, marginal zone B1 protein and leucine-rich α2-glycoprotein-1 as biomarkers for disease severity and fibrosis in systemic sclerosis patients.循环细胞角蛋白 17、边缘区 B1 蛋白和富含亮氨酸的α2-糖蛋白 1 作为系统性硬化症患者疾病严重程度和纤维化的生物标志物。
Biochem Med (Zagreb). 2022 Oct 1;32(3):030707. doi: 10.11613/BM.2022.030707.
6
Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.系统性硬皮病患者血清表面活性蛋白 D 浓度：间质性肺病严重程度的潜在标志物。
Best Pract Res Clin Rheumatol. 2018 Aug;32(4):541-549. doi: 10.1016/j.berh.2019.01.005. Epub 2019 Feb 14.
7
Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.候选血清生物标志物在系统性硬化症相关间质性肺病中的表现。
Arthritis Rheumatol. 2019 Jun;71(6):972-982. doi: 10.1002/art.40815. Epub 2019 Apr 26.
8
Endocan, Novel Potential Biomarker for Systemic Sclerosis: Results of a Pilot Study.内脂素，系统性硬化症的新型潜在生物标志物：一项初步研究的结果
J Clin Lab Anal. 2016 Sep;30(5):368-73. doi: 10.1002/jcla.21864. Epub 2015 Sep 1.
9
Brief report: lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosis.简要报告：赖氨酰氧化酶是系统性硬化症纤维化的潜在生物标志物。
Arthritis Rheumatol. 2014 Mar;66(3):726-30. doi: 10.1002/art.38277.
10
Association of simple hematological parameters with disease manifestations, activity, and severity in patients with systemic sclerosis.简单血液学参数与系统性硬化症患者疾病表现、活动度和严重程度的相关性。
Clin Rheumatol. 2020 Jan;39(1):77-83. doi: 10.1007/s10067-019-04685-0. Epub 2019 Jul 18.

引用本文的文献

1
Low serum S100A6 levels are associated RP-ILD risk in anti-MDA5-positive dermatomyositis.血清S100A6水平低与抗MDA5阳性皮肌炎患者发生RP-ILD的风险相关。
Clin Rheumatol. 2025 Jan;44(1):341-348. doi: 10.1007/s10067-024-07265-z. Epub 2024 Dec 16.
2
S100A6: molecular function and biomarker role.S100A6：分子功能与生物标志物作用
Biomark Res. 2023 Sep 5;11(1):78. doi: 10.1186/s40364-023-00515-3.
3
Current Perspectives on Periodontitis in Systemic Sclerosis: Associative Relationships, Pathogenic Links, and Best Practices.

本文引用的文献

1
Calumenin contributes to epithelial-mesenchymal transition and predicts poor survival in glioma.钙网蛋白促进胶质瘤上皮-间质转化并预示预后不良。
Transl Neurosci. 2021 Feb 3;12(1):67-75. doi: 10.1515/tnsci-2021-0004. eCollection 2021 Jan 1.
2
Candidate proteomic biomarkers in systemic sclerosis discovered using mass-spectrometry: an update of a systematic review (2014-2020).基于质谱的系统性硬化症候选蛋白生物标志物的研究进展：一项系统性综述的更新（2014-2020）。
Rom J Intern Med. 2021 May 8;59(2):101-111. doi: 10.2478/rjim-2020-0037. Print 2021 Jun 1.
3
Involvement of RAGE and Oxidative Stress in Inflammatory and Infectious Skin Diseases.
系统性硬化症中牙周炎的当前观点：关联关系、致病联系及最佳实践
Diagnostics (Basel). 2023 Feb 22;13(5):841. doi: 10.3390/diagnostics13050841.
4
S100A6 participates in initiation of autoimmune encephalitis and is under epigenetic control.S100A6 参与自身免疫性脑炎的启动，受表观遗传控制。
Brain Behav. 2023 Mar;13(3):e2897. doi: 10.1002/brb3.2897. Epub 2023 Feb 7.
5
Circulatory cytokeratin 17, marginal zone B1 protein and leucine-rich α2-glycoprotein-1 as biomarkers for disease severity and fibrosis in systemic sclerosis patients.循环细胞角蛋白 17、边缘区 B1 蛋白和富含亮氨酸的α2-糖蛋白 1 作为系统性硬化症患者疾病严重程度和纤维化的生物标志物。
Biochem Med (Zagreb). 2022 Oct 1;32(3):030707. doi: 10.11613/BM.2022.030707.
6
Personalized Medicine in the Field of Inflammatory Skin Disorders.炎症性皮肤病领域的个性化医疗
J Pers Med. 2022 Mar 9;12(3):426. doi: 10.3390/jpm12030426.
晚期糖基化终末产物受体（RAGE）与氧化应激在炎症性和感染性皮肤病中的作用
Antioxidants (Basel). 2021 Jan 9;10(1):82. doi: 10.3390/antiox10010082.
4
The GEF Cytohesin-2/ARNO Mediates Resistin induced Phenotypic Switching in Vascular Smooth Muscle Cells.GEF Cytohesin-2/ARNO 介导抵抗素诱导的血管平滑肌细胞表型转换。
Sci Rep. 2020 Feb 28;10(1):3672. doi: 10.1038/s41598-020-60446-z.
5
Up-regulation of IGF-1, RANTES and VEGF in patients with anti-centromere antibody-positive early/mild systemic sclerosis.抗着丝点抗体阳性早期/轻度系统性硬化症患者中 IGF-1、RANTES 和 VEGF 的上调。
Mod Rheumatol. 2021 Jan;31(1):171-176. doi: 10.1080/14397595.2020.1726599. Epub 2020 Feb 17.
6
Quantification of Calcyclin and Heat Shock Protein 90 in Sera from Women with and without Preeclampsia by Mass Spectrometry.采用质谱法对先兆子痫患者和非患者血清中的钙调蛋白和热休克蛋白 90 进行定量分析。
Proteomics Clin Appl. 2019 May;13(3):e1800181. doi: 10.1002/prca.201800181. Epub 2018 Nov 26.
7
Protective effect of miR378* on doxorubicin-induced cardiomyocyte injury via calumenin.miR378* 通过钙网蛋白对阿霉素诱导的心肌细胞损伤的保护作用。
J Cell Physiol. 2018 Oct;233(10):6344-6351. doi: 10.1002/jcp.26615. Epub 2018 Apr 17.
8
Proteomics detection of S100A6 in tumor tissue interstitial fluid and evaluation of its potential as a biomarker of cholangiocarcinoma.肿瘤组织间质液中S100A6的蛋白质组学检测及其作为胆管癌生物标志物潜力的评估。
Tumour Biol. 2018 Apr;40(4):1010428318767195. doi: 10.1177/1010428318767195.
9
Circulating Reticulocalbin 1 and Reticulocalbin 3 in Systemic Sclerosis Patients: Results of a Case Control Study.系统性硬化症患者循环中的网织钙结合蛋白1和网织钙结合蛋白3：一项病例对照研究的结果
Clin Lab. 2016;62(6):1109-16.
10
Biomarkers in systemic sclerosis: Their potential to predict clinical courses.系统性硬化症中的生物标志物：其预测临床病程的潜力。
J Dermatol. 2016 Jan;43(1):29-38. doi: 10.1111/1346-8138.13156.